Ligand Pharmaceuticals Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LGND research report →
Range $326 – $406
Price Chart
About the company
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients.
- CEO
- Todd C. Davis
- IPO
- 1992
- Employees
- 47
- HQ
- Jupiter, FL, US
Get TickerSpark's AI analysis on LGND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.74B
- P/E
- 113.44
- Fwd P/E
- 29.94
- PEG
- 13.56
- P/S
- 23.15
- P/B
- 6.10
- EV/EBITDA
- 86.61
- Div Yield
- 0.00%
- Gross Margin
- 107.11%
- Op Margin
- 11.91%
- Net Margin
- 20.27%
- ROE
- 5.22%
- ROIC
- 1.35%
Latest fiscal year · YoY change
- Revenue
- $268.09M+60.4%
- Gross Profit
- $261.50M+67.6%
- Op Income
- $47.20M
- Net Income
- $124.45M+3186.6%
- EPS
- $6.44+3027.3%
- OCF Growth
- -49.1%
- FCF Growth
- -36.8%
- 52W High
- $326.63
- 52W Low
- $106.30
- 50D MA
- $302.30
- 200D MA
- $260.34
- Beta
- 1.03
- RSI (14)
- 39
- Avg Volume
- 229.12K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ligand delivered strong third-quarter royalty growth, raised full-year EPS guidance, and said its expanded XOMA-backed portfolio is creating more growth and catalyst opportunities.· October 29, 2026
- Royalty revenue rose 51% year over year to $70.3 million, driven by Filspari, Ohtuvayre and the newly added XOMA assets.
- Adjusted diluted EPS was $2.67 versus $3.09 last year, with the prior-year quarter benefiting from $24.5 million of Zelsuvmi out-license income.
- Management raised 2026 adjusted EPS guidance to $9.50 to $9.75, while reaffirming revenue guidance.
- Ligand said it has about $750 million of deployable capital and more than 180 opportunities reviewed this year.
- The company highlighted up to seven pivotal readouts through 2027, including five from the XOMA acquisition.
Royalty revenue was $70.3 million in the quarter, up 51% year over year. Total core revenue was $78.7 million, down 9% versus $86.9 million last year, because the prior-year quarter included $24.5 million of Zelsuvmi out-license income; excluding that, core revenue grew 26%. Adjusted diluted EPS was $2.67 compared with $3.09 a year ago, while GAAP net loss was $28.5 million, or $1.43 per share, versus net income of $117.3 million, or $5.68 per share, last year. Cash, cash equivalents and short-term investments were approximately $450 million at quarter end, and Ligand said it had about $750 million of deployable capital including equity holdings and its credit facility. For 2026, the company reaffirmed royalty revenue guidance of $225 million to $250 million, total revenue of $270 million to $310 million, Captisol revenue of $35 million to $40 million, and contract revenue of $10 million to $20 million, while raising adjusted diluted EPS guidance to $9.50 to $9.75 from $9.00 to $9.50.
Todd Davis said the quarter marked an important inflection point, citing 51% royalty growth, the XOMA acquisition, and a larger, more diversified portfolio. He emphasized that Ligand is now a capital-light royalty aggregator with a disciplined investment process and a growing opportunity set, including more than 200 assets and up to seven pivotal readouts through 2027. His tone was confident and expansionary, but he also stressed selectivity and diversification rather than dependence on any single catalyst.
Tavo Espinoza focused on the mechanics behind the quarter and the guidance. He said the company ended with about $450 million in cash, cash equivalents and short-term investments, and around $750 million of deployable capital when including equity holdings and the credit facility. He also noted that the financial royalty asset balance rose from about $200 million last quarter to $800 million after XOMA, and that 2026 core cash operating expenses remain on track at approximately $50 million, including XOMA. On capital structure, he said Ligand has $460 million of 75 basis point notes due 2030 and $700 million of 0% notes due 2031, both paired with call spreads and net share settled.
Analysts pressed management on whether XOMA’s portfolio held additional value beyond the initial underwriting, and Todd Davis said the company is finding “option value” in assets that were initially underwritten to zero. They also asked whether XOMA contribution guidance has changed; management said there is no change and reiterated the expected contribution remains $0.50 in 2026 and $1.50 in 2027. Questions on guidance conservatism drew a response that the company is more confident on EPS than revenue because top-line timing depends on Captisol orders and partner milestones, while the fourth quarter should benefit from a full quarter of XOMA royalties and higher tiered rates. Analysts also asked about QTORIN rapamycin and Ryjunea, with management pointing to strong commercial potential for QTORIN if approved and saying Ryjunea’s European approval is already established and not viewed as carrying read-across risk from U.S. regulatory scrutiny.
The bull case from this call is that Ligand’s royalty base is growing quickly while the company is adding more assets and more shot-on-goal catalysts. Management said the portfolio now exceeds 200 commercial, clinical and preclinical assets, deployable capital is ample, and XOMA is already adding both commercial royalties and development-stage optionality. The raised EPS guide and confidence in continued growth from Filspari, Ohtuvayre and new assets like Ryjunea support the idea that the model is scaling well.
The main risks discussed were timing and binary clinical/regulatory events. Management repeatedly said revenue can shift by quarter because of partner reporting delays, Captisol order timing and milestone volatility, and that many upcoming readouts may not be positive. They also acknowledged that the Q4 revenue range is cautious and that results from assets like QTORIN, Palvella and multiple XOMA pipeline programs remain uncertain until data and approvals arrive.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.8%
- Shares Outstanding
- 20.00M
- Float Shares
- 19.55M
of shares held by institutions
432 13F filers
Buy/sell ratio 0.06. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for LGND, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | May 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 15, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 5, 26 | Filing → |
| Katherine M. ClarkHouse · MA05 | Sell | Oct 22, 20 | Filing → |
| Katherine M. ClarkHouse · MA05 | Buy | Apr 3, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.11M | ▲ 11.21K |
| Vanguard Group Inc | 2.07M | ▼ 2.39K |
| Invesco Ltd. | 1.50M | ▲ 302.06K |
| Vanguard Portfolio Management LLC | 1.11M | ▼ 26.27K |
| Jupiter Topco LLC | 1.04M | ▲ 1.04M |
| Janus Henderson Group Ltd. | 1.01M | ▲ 14.49K |
| Franklin Templeton Inc | 912.31K | ▲ 160.27K |
| Vanguard Capital Management LLC | 869.48K | ▼ 1.47K |
| State Street Corp | 834.68K | ▲ 8.15K |
| Fmr LLC | 698.92K | ▼ 63.91K |
| Congress Asset Management Co | 658.56K | ▼ 1.35K |
| Geode Capital Management, LLC | 586.81K | ▼ 2.21K |
Held by 465 ETFs
Biggest fund positions in LGND by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | KOZARICH JOHN W | sell | 500 |
| Nov 12, 26 | Zimmermann Martine | sell | 2,000 |
| Nov 10, 26 | Aryeh Jason | sell | 500 |
| Nov 10, 26 | Aryeh Jason | sell | 844 |
| Nov 10, 26 | Aryeh Jason | sell | 646 |
| Nov 10, 26 | Aryeh Jason | sell | 10 |
| Nov 10, 26 | Aryeh Jason | sell | 500 |
| Nov 10, 26 | Aryeh Jason | sell | 500 |
| Nov 4, 26 | Aryeh Jason | sell | 282 |
| Nov 2, 26 | Reardon Andrew | other | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LGND coverage
Recent articles, reports, and earnings notes.
No research on LGND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LGND report →Ligand Pharmaceuticals (NASDAQ:LGND) & Applied Therapeutics (NASDAQ:APLT) Head to Head Comparison
defenseworld.net · Nov 19
3,096 Ligand Pharmaceuticals Incorporated $LGND Shares Acquired by Bessemer Group Inc.
defenseworld.net · Nov 17
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Crosses Below 50-Day Moving Average After Insider Selling
defenseworld.net · Nov 17
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock
defenseworld.net · Nov 7
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock
defenseworld.net · Nov 7
Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy
seekingalpha.com · Nov 4
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 30
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
marketbeat.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.